ArticleTransgender health2024
Gender-Affirming Hormone Therapy Is Associated with Increased Odds of Screening for Sexually Transmitted Infections in a Clinical Cohort of Transgender and Nonbinary Adults.
Article in Transgender health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transgender and gender diverse persons' sexually transmitted infection testing: a mixed methods study to understand primary care providers' training gaps and desires to promote sexual health equity.BMC health services research · 2026Article
- Transphobia in the United Kingdom: a public health crisis.International journal for equity in health · 2025Article
- Characterizing disparities in the HIV care continuum among U.S. transgender and cisgender Medicare beneficiaries, 2008-2017.AIDS care · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Transgender and nonbinary adults (TNB) are disproportionately burdened by sexually transmitted infections (STI) and the human immunodeficiency virus (HIV). This study investigated whether gender-affirming hormone therapy was associated with TNB adults' odds of screening for STI and HIV. Methods: Longitudinal data came from the electronic medical records of TNB primary care patients receiving care at two community health centers located in Boston, Massachusetts, and New York City, New York, between January 2013 and December 2019. Missing data were addressed using multiple imputation with chained equations, and statistical analyses included the use of unadjusted and covariate-adjusted logistic generalized estimating equation models. Models examined whether gender-affirming hormone therapy was significantly associated with patients' concurrent odds of STI and HIV screening between 2016 and 2019 (i.e., patients screening within the same year they had an active hormone prescription). Results: Gender-affirming hormone therapy was associated with statistically significant higher odds of STI screening (chlamydia and gonorrhea), but not HIV screening, among TNB patients (STI screening: adjusted odds ratio [aOR] = 1.25, 95% confidence interval [CI] = [1.05, 1.49]; HIV screening: aOR = 1.21, 95% CI = [1.00, 1.47]). Additionally, taking preexposure prophylaxis (PrEP) for HIV prevention was associated with increased odds of both STI and HIV screening (STI screening: aOR = 3.74, 95% CI = [1.82, 7.71]; HIV screening: aOR = 4.41, 95% CI = [2.25, 8.64]). Conclusion: Primary care appointments for the provision of gender-affirming hormones may be an opportune time to incorporate routine STI/HIV screening for sexually active TNB patients. The provision of gender-affirming hormone therapy and PrEP may increase patients' odds of routine STI/HIV screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.